{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T04:27:08Z","timestamp":1792988828217,"version":"4.5.0"},"reference-count":182,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1378\/chest.11-2303","type":"journal-article","created":{"date-parts":[[2012,2,7]],"date-time":"2012-02-07T02:39:00Z","timestamp":1328582340000},"page":"e495S-e530S","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":818,"special_numbering":"S","title":["Treatment and Prevention of Heparin-Induced Thrombocytopenia"],"prefix":"10.1016","volume":"141","author":[{"given":"Lori-Ann","family":"Linkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio L.","family":"Dans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Moores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Schulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Crowther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2 suppl","key":"10.1378\/chest.11-2303_bib1","doi-asserted-by":"crossref","first-page":"53S","DOI":"10.1378\/chest.11-2288","article-title":"Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Guyatt","year":"2012","journal-title":"Chest"},{"issue":"2 suppl","key":"10.1378\/chest.11-2303_bib2","doi-asserted-by":"crossref","first-page":"e1S","DOI":"10.1378\/chest.11-2290","article-title":"Patient values and preferences in decision making for antithrombotic therapy: a systematic review: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"MacLean","year":"2012","journal-title":"Chest"},{"issue":"20","key":"10.1378\/chest.11-2303_bib3","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin","volume":"332","author":"Warkentin","year":"1995","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1378\/chest.11-2303_bib4","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/archinte.163.20.2518","article-title":"An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients","volume":"163","author":"Warkentin","year":"2003","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1378\/chest.11-2303_bib5","first-page":"132","article-title":"Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients","volume":"94","author":"Greinacher","year":"2005","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1378\/chest.11-2303_bib6","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0002-9343(96)00258-6","article-title":"A 14-year study of heparin-induced thrombocytopenia","volume":"101","author":"Warkentin","year":"1996","journal-title":"Am J Med"},{"issue":"2","key":"10.1378\/chest.11-2303_bib7","first-page":"247","article-title":"Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen","volume":"71","author":"Greinacher","year":"1994","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1378\/chest.11-2303_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-0038-1656329","article-title":"Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia","volume":"68","author":"Amiral","year":"1992","journal-title":"Thromb Haemost"},{"issue":"11","key":"10.1378\/chest.11-2303_bib9","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1182\/blood.V83.11.3232.3232","article-title":"Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4","volume":"83","author":"Kelton","year":"1994","journal-title":"Blood"},{"issue":"2","key":"10.1378\/chest.11-2303_bib10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.1989.tb00258.x","article-title":"Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets","volume":"73","author":"Chong","year":"1989","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1378\/chest.11-2303_bib11","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V84.11.3691.bloodjournal84113691","article-title":"Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia","volume":"84","author":"Warkentin","year":"1994","journal-title":"Blood"},{"issue":"5","key":"10.1378\/chest.11-2303_bib12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/09537109975960","article-title":"Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG\/serum and other IgG platelet agonists: a comparison with standard platelet agonists","volume":"10","author":"Warkentin","year":"1999","journal-title":"Platelets"},{"issue":"8","key":"10.1378\/chest.11-2303_bib13","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1182\/blood-2005-04-1546","article-title":"Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis","volume":"106","author":"Martel","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1378\/chest.11-2303_bib14","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood.V96.5.1703","article-title":"Impact of the patient population on the risk for heparin-induced thrombocytopenia","volume":"96","author":"Warkentin","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1378\/chest.11-2303_bib15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.lab.2005.08.003","article-title":"Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?","volume":"146","author":"Warkentin","year":"2005","journal-title":"J Lab Clin Med"},{"issue":"4","key":"10.1378\/chest.11-2303_bib16","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1046\/j.1365-2141.2002.03687.x","article-title":"Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin","volume":"118","author":"Lindhoff-Last","year":"2002","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1378\/chest.11-2303_bib17","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/blood-2009-07-231506","article-title":"The severity of trauma determines the immune response to PF4\/heparin and the frequency of heparin-induced thrombocytopenia","volume":"115","author":"Lubenow","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1378\/chest.11-2303_bib18","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1182\/blood-2005-11-012450","article-title":"Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia","volume":"108","author":"Warkentin","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1378\/chest.11-2303_bib19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.thromres.2007.11.007","article-title":"Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings","volume":"122","author":"Greinacher","year":"2008","journal-title":"Thromb Res"},{"issue":"3","key":"10.1378\/chest.11-2303_bib20","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1538-7836.2009.03735.x","article-title":"Anti-PF4\/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization","volume":"8","author":"Warkentin","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1378\/chest.11-2303_bib21","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1055\/s-0037-1614550","article-title":"Safety of low-molecular-weight heparin in pregnancy: a systematic review","volume":"81","author":"Sanson","year":"1999","journal-title":"Thromb Haemost"},{"issue":"11","key":"10.1378\/chest.11-2303_bib22","first-page":"1134","article-title":"Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies","volume":"108","author":"Lepercq","year":"2001","journal-title":"BJOG"},{"issue":"1","key":"10.1378\/chest.11-2303_bib23","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1067\/mob.2001.114690","article-title":"Heparin-induced thrombocytopenia is rare in pregnancy","volume":"185","author":"Fausett","year":"2001","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"10.1378\/chest.11-2303_bib24","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2002-07-2201","article-title":"The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study","volume":"101","author":"Girolami","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1378\/chest.11-2303_bib25","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2005-05-1824","article-title":"Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia","volume":"106","author":"Greinacher","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1378\/chest.11-2303_bib26","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.amjmed.2009.03.026","article-title":"Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism","volume":"122","author":"Stein","year":"2009","journal-title":"Am J Med"},{"issue":"19","key":"10.1378\/chest.11-2303_bib27","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1161\/01.CIR.99.19.2530","article-title":"Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin:clinical implications for heparin-induced thrombocytopenia","volume":"99","author":"Pouplard","year":"1999","journal-title":"Circulation"},{"issue":"6","key":"10.1378\/chest.11-2303_bib28","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1365-2141.2005.05381.x","article-title":"Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies","volume":"128","author":"Pouplard","year":"2005","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1378\/chest.11-2303_bib29","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ahj.2010.05.026","article-title":"Incidence and clinical relevance of anti-platelet factor 4\/heparin antibodies before cardiac surgery","volume":"160","author":"Selleng","year":"2010","journal-title":"Am Heart J"},{"issue":"9","key":"10.1378\/chest.11-2303_bib30","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood-2005-03-0912","article-title":"The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study","volume":"106","author":"Prandoni","year":"2005","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1378\/chest.11-2303_bib31","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1016\/S0049-3848(07)70143-3","article-title":"Cancer, thrombosis and heparin-induced thrombocytopenia","volume":"120","author":"Prandoni","year":"2007","journal-title":"Thromb Res"},{"issue":"2","key":"10.1378\/chest.11-2303_bib32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jcrc.2009.12.006","article-title":"The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients","volume":"25","author":"Crowther","year":"2010","journal-title":"J Crit Care"},{"issue":"6","key":"10.1378\/chest.11-2303_bib33","first-page":"425","article-title":"Serologic evidence of heparin sensitization in cancer patients receiving heparin flushes of venous access devices","volume":"7","author":"Mayo","year":"1999","journal-title":"Support Care Cancer"},{"issue":"9","key":"10.1378\/chest.11-2303_bib34","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1471-0528.2000.tb11110.x","article-title":"Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy","volume":"107","author":"Ellison","year":"2000","journal-title":"BJOG"},{"issue":"2","key":"10.1378\/chest.11-2303_bib35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2005-02-0626","article-title":"Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy","volume":"106","author":"Greer","year":"2005","journal-title":"Blood"},{"issue":"17","key":"10.1378\/chest.11-2303_bib36","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1056\/NEJM200104263441704","article-title":"Temporal aspects of heparin-induced thrombocytopenia","volume":"344","author":"Warkentin","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1378\/chest.11-2303_bib37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1378\/chest.122.1.37","article-title":"Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin","volume":"122","author":"Lubenow","year":"2002","journal-title":"Chest"},{"issue":"7","key":"10.1378\/chest.11-2303_bib38","doi-asserted-by":"crossref","first-page":"502","DOI":"10.7326\/0003-4819-135-7-200110020-00009","article-title":"Delayed-onset heparin-induced thrombocytopenia and thrombosis","volume":"135","author":"Warkentin","year":"2001","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1378\/chest.11-2303_bib39","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/S0003-4975(99)00827-9","article-title":"Blood product use in cardiac revascularization: comparison of on- and off-pump techniques","volume":"68","author":"Nader","year":"1999","journal-title":"Ann Thorac Surg"},{"issue":"11","key":"10.1378\/chest.11-2303_bib40","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1111\/j.1538-7836.2004.01016.x","article-title":"Towards a diagnosis of heparin-induced thrombocytopenia after cardiopulmonary bypass","volume":"2","author":"Matthai","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1378\/chest.11-2303_bib41","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/j.1538-7836.2004.00949.x","article-title":"Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass","volume":"2","author":"Lillo-Le Lou\u00ebt","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1378\/chest.11-2303_bib42","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0002-9343(99)00124-2","article-title":"Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia","volume":"106","author":"Wallis","year":"1999","journal-title":"Am J Med"},{"issue":"1","key":"10.1378\/chest.11-2303_bib43","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-8652(199709)56:1<12::AID-AJH3>3.0.CO;2-5","article-title":"Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution","volume":"56","author":"Nand","year":"1997","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1378\/chest.11-2303_bib44","doi-asserted-by":"crossref","first-page":"M574","DOI":"10.1097\/00002480-199207000-00100","article-title":"Heparin induced thrombocytopenia in patients undergoing intra-aortic balloon pumping after open heart surgery","volume":"38","author":"Walls","year":"1992","journal-title":"ASAIO J"},{"issue":"5","key":"10.1378\/chest.11-2303_bib45","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1378\/chest.104.5.1436","article-title":"Complications from heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass","volume":"104","author":"Singer","year":"1993","journal-title":"Chest"},{"issue":"9","key":"10.1378\/chest.11-2303_bib46","doi-asserted-by":"crossref","first-page":"804","DOI":"10.7326\/0003-4819-127-9-199711010-00005","article-title":"The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia","volume":"127","author":"Warkentin","year":"1997","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1378\/chest.11-2303_bib47","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1046\/j.1365-2141.1996.d01-1481.x","article-title":"Heparin-induced skin lesions","volume":"92","author":"Warkentin","year":"1996","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1378\/chest.11-2303_bib48","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1378\/chest.127.5.1857","article-title":"Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study","volume":"127","author":"Warkentin","year":"2005","journal-title":"Chest"},{"issue":"4","key":"10.1378\/chest.11-2303_bib49","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2141.1983.tb02146.x","article-title":"Heparin-induced thrombocytopenia with associated disseminated intravascular coagulation","volume":"54","author":"Zalcberg","year":"1983","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1378\/chest.11-2303_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0037-1614206","article-title":"Heparin-induced thrombocytopenia: towards consensus","volume":"79","author":"Warkentin","year":"1998","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1378\/chest.11-2303_bib51","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1538-7836.2006.01787.x","article-title":"Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings [see comment]","volume":"4","author":"Lo","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1378\/chest.11-2303_bib52","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/ajcp\/111.5.700","article-title":"Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia","volume":"111","author":"Pouplard","year":"1999","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1378\/chest.11-2303_bib53","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1537-2995.1994.34594249047.x","article-title":"Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4\/heparin enzyme-linked immunosorbent assay","volume":"34","author":"Greinacher","year":"1994","journal-title":"Transfusion"},{"issue":"2","key":"10.1378\/chest.11-2303_bib54","first-page":"85","article-title":"Orgaran in heparin-induced thrombocytopenia","volume":"22","author":"Chong","year":"1992","journal-title":"Haemostasis"},{"issue":"12","key":"10.1378\/chest.11-2303_bib55","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1111\/j.1538-7836.2010.04059.x","article-title":"The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion","volume":"8","author":"Cuker","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1378\/chest.11-2303_bib56","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/j.1538-7836.2007.02524.x","article-title":"Prospective evaluation of the \u20184Ts\u2019 score and particle gel immunoassay specific to heparin\/PF4 for the diagnosis of heparin-induced thrombocytopenia [see comment]","volume":"5","author":"Pouplard","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1378\/chest.11-2303_bib57","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2141.2008.07401.x","article-title":"Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4Ts score and particle gel immunoassay","volume":"143","author":"Bryant","year":"2008","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1378\/chest.11-2303_bib58","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.thromres.2008.04.020","article-title":"A clinical-laboratory approach contributing to a rapid and reliable diagnosis of heparin-induced thrombocytopenia","volume":"123","author":"Denys","year":"2008","journal-title":"Thromb Res"},{"issue":"7","key":"10.1378\/chest.11-2303_bib59","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/j.1538-7836.2010.03880.x","article-title":"Non-necrotizing heparin-induced skin lesions and the 4Ts score","volume":"8","author":"Warkentin","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1378\/chest.11-2303_bib60","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1111\/j.1538-7836.2005.01623.x","article-title":"Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3","volume":"3","author":"Lubenow","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1378\/chest.11-2303_bib61","first-page":"1357","article-title":"Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: a survey of North American specialized coagulation laboratories","volume":"98","author":"Price","year":"2007","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1378\/chest.11-2303_bib62","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1055\/s-2004-831049","article-title":"A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex","volume":"30","author":"Francis","year":"2004","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"10.1378\/chest.11-2303_bib63","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1055\/s-2008-1047564","article-title":"The approach to heparin-induced thrombocytopenia","volume":"29","author":"Linkins","year":"2008","journal-title":"Semin Respir Crit Care Med"},{"issue":"3","key":"10.1378\/chest.11-2303_bib64","first-page":"371","article-title":"Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia","volume":"120","author":"Warkentin","year":"1992","journal-title":"J Lab Clin Med"},{"issue":"6","key":"10.1378\/chest.11-2303_bib65","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1055\/s-0038-1646493","article-title":"A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia","volume":"66","author":"Greinacher","year":"1991","journal-title":"Thromb Haemost"},{"issue":"8","key":"10.1378\/chest.11-2303_bib66","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/j.1538-7836.2007.02617.x","article-title":"Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4\/heparin antibodies of the IgG, IgM, and IgA classes","volume":"5","author":"Greinacher","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"9189","key":"10.1378\/chest.11-2303_bib67","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(99)03625-9","article-title":"Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID-HPF4)","volume":"354","author":"Meyer","year":"1999","journal-title":"Lancet"},{"issue":"8","key":"10.1378\/chest.11-2303_bib68","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/j.1538-7836.2009.03465.x","article-title":"Prospective evaluation of PF4\/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia","volume":"7","author":"Bakchoul","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1378\/chest.11-2303_bib69","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1538-7836.2008.03025.x","article-title":"Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays","volume":"6","author":"Warkentin","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"12","key":"10.1378\/chest.11-2303_bib70","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/j.1538-7836.2004.01039.x","article-title":"Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia","volume":"2","author":"Zwicker","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1378\/chest.11-2303_bib71","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1600-0609.2008.01035.x","article-title":"Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia","volume":"80","author":"Altuntas","year":"2008","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1378\/chest.11-2303_bib72","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/ajh.21032","article-title":"What is the potential for overdiagnosis of heparin-induced thrombocytopenia?","volume":"82","author":"Lo","year":"2007","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1378\/chest.11-2303_bib73","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1345\/aph.1L646","article-title":"Compliance with platelet count monitoring recommendations and management of possible heparin-induced thrombocytopenia in hospitalized patients receiving low-molecular-weight heparin","volume":"43","author":"ten Berg","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1378\/chest.11-2303_bib74","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s11239-008-0279-x","article-title":"Effectiveness of a clinical decision support system to identify heparin induced thrombocytopenia","volume":"28","author":"Riggio","year":"2009","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"10.1378\/chest.11-2303_bib75","first-page":"66","article-title":"The monitoring of heparin induced thrombocytopenia following surgery: an audit and international survey","volume":"20","author":"Rogers","year":"2010","journal-title":"J Perioper Pract"},{"issue":"6 suppl","key":"10.1378\/chest.11-2303_bib76","doi-asserted-by":"crossref","first-page":"340S","DOI":"10.1378\/chest.08-0677","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)","volume":"133","author":"Warkentin","year":"2008","journal-title":"Chest"},{"issue":"9","key":"10.1378\/chest.11-2303_bib77","first-page":"632","article-title":"Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients","volume":"10","author":"McGarry","year":"2004","journal-title":"Am J Manag Care"},{"issue":"6","key":"10.1378\/chest.11-2303_bib78","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1378\/chest.129.6.1407","article-title":"Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia [see comment]","volume":"129","author":"Lewis","year":"2006","journal-title":"Chest"},{"issue":"6","key":"10.1378\/chest.11-2303_bib79","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/01.CIR.100.6.587","article-title":"Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators","volume":"100","author":"Greinacher","year":"1999","journal-title":"Circulation"},{"issue":"1","key":"10.1378\/chest.11-2303_bib80","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/01.CIR.99.1.73","article-title":"Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study","volume":"99","author":"Greinacher","year":"1999","journal-title":"Circulation"},{"issue":"14","key":"10.1378\/chest.11-2303_bib81","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/01.CIR.103.14.1838","article-title":"Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia","volume":"103","author":"Lewis","year":"2001","journal-title":"Circulation"},{"issue":"15","key":"10.1378\/chest.11-2303_bib82","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/archinte.163.15.1849","article-title":"Argatroban anticoagulation in patients with heparin-induced thrombocytopenia","volume":"163","author":"Lewis","year":"2003","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1378\/chest.11-2303_bib83","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1182\/blood-2004-02-0621","article-title":"Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies","volume":"104","author":"Lubenow","year":"2004","journal-title":"Blood"},{"issue":"2 suppl","key":"10.1378\/chest.11-2303_bib84","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"issue":"5","key":"10.1378\/chest.11-2303_bib85","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1055\/s-0038-1656063","article-title":"Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial","volume":"77","author":"Schiele","year":"1997","journal-title":"Thromb Haemost"},{"issue":"11","key":"10.1378\/chest.11-2303_bib86","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM199609123351103","article-title":"A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators","volume":"335","year":"1996","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1378\/chest.11-2303_bib87","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0735-1097(99)00107-2","article-title":"A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study","volume":"33","author":"Jang","year":"1999","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1378\/chest.11-2303_bib88","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1023\/A:1026591023462","article-title":"Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study","volume":"10","author":"Vermeer","year":"2000","journal-title":"J Thromb Thrombolysis"},{"issue":"2\u20133","key":"10.1378\/chest.11-2303_bib89","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0049-3848(03)00336-0","article-title":"Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban","volume":"110","author":"Warkentin","year":"2003","journal-title":"Thromb Res"},{"issue":"12","key":"10.1378\/chest.11-2303_bib90","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1592\/phco.2005.25.12.1736","article-title":"Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia","volume":"25","author":"Kiser","year":"2005","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1378\/chest.11-2303_bib91","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/107602960501100403","article-title":"A comparison of lepirudin and argatroban outcomes","volume":"11","author":"Smythe","year":"2005","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"10.1378\/chest.11-2303_bib92","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11239-008-0275-1","article-title":"A comparison of direct thrombin inhibitors in the treatment of Heparin-Induced Thrombocytopenia: a single institution experience","volume":"28","author":"Curzio","year":"2009","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"10.1378\/chest.11-2303_bib93","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1055\/s-0037-1616046","article-title":"Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study","volume":"86","author":"Chong","year":"2001","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1378\/chest.11-2303_bib94","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1055\/s-0037-1615946","article-title":"A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia","volume":"85","author":"Farner","year":"2001","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1378\/chest.11-2303_bib95","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.thromres.2005.04.011","article-title":"Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and\/or coumarin explain the rapid shift in clinical practice during the 1990s","volume":"117","author":"Lubenow","year":"2006","journal-title":"Thromb Res"},{"issue":"6","key":"10.1378\/chest.11-2303_bib96","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/1076029609347900","article-title":"Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience","volume":"16","author":"Grouzi","year":"2010","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"10.1378\/chest.11-2303_bib97","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1160\/TH07-04-0252","article-title":"Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia","volume":"99","author":"Lobo","year":"2008","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1378\/chest.11-2303_bib98","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/MJT.0b013e3181f65503","article-title":"A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study","volume":"18","author":"Boyce","year":"2011","journal-title":"Am J Ther"},{"issue":"9","key":"10.1378\/chest.11-2303_bib99","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1592\/phco.28.9.1115","article-title":"Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia","volume":"28","author":"Kiser","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"suppl 1","key":"10.1378\/chest.11-2303_bib100","first-page":"164a","article-title":"Bivalirudin, a direct thrombin inhibitor, is a safe and effective treatment for heparin-induced thrombocytopenia [abstract]","volume":"102","author":"Francis","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1378\/chest.11-2303_bib101","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1592\/phco.26.4.461","article-title":"Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia","volume":"26","author":"Dang","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"25","key":"10.1378\/chest.11-2303_bib102","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1056\/NEJMc070346","article-title":"Heparin-induced thrombocytopenia associated with fondaparinux","volume":"356","author":"Warkentin","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1378\/chest.11-2303_bib103","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1160\/TH07-09-0573","article-title":"Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT)","volume":"99","author":"Rota","year":"2008","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1378\/chest.11-2303_bib104","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1160\/TH10-05-0284","article-title":"Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke","volume":"104","author":"Salem","year":"2010","journal-title":"Thromb Haemost"},{"issue":"7","key":"10.1378\/chest.11-2303_bib105","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1538-7836.2008.02973.x","article-title":"Can heparin-induced thrombocytopenia be associated with fondaparinux use? A rebuttal","volume":"6","author":"Elalamy","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1378\/chest.11-2303_bib106","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/ajh.21273","article-title":"Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis","volume":"83","author":"Alsaleh","year":"2008","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1378\/chest.11-2303_bib107","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2006-02-001057","article-title":"Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin","volume":"108","author":"Tardy","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1378\/chest.11-2303_bib108","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11239-006-9019-2","article-title":"Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia","volume":"22","author":"Guzzi","year":"2006","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"10.1378\/chest.11-2303_bib109","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00002018-200932030-00003","article-title":"Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia","volume":"32","author":"Hursting","year":"2009","journal-title":"Drug Saf"},{"issue":"5","key":"10.1378\/chest.11-2303_bib110","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJM197607292950501","article-title":"Heparin-induced immune thrombocytopenia","volume":"295","author":"Babcock","year":"1976","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1378\/chest.11-2303_bib111","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ajh.2830060204","article-title":"Heparin-induced thrombocytopenia: association with a platelet aggregating factor and arterial thromboses","volume":"6","author":"Cimo","year":"1979","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1378\/chest.11-2303_bib112","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1111\/j.1538-7836.2010.03861.x","article-title":"Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia","volume":"8","author":"Refaai","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1378\/chest.11-2303_bib113","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archinte.164.1.66","article-title":"Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia","volume":"164","author":"Srinivasan","year":"2004","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1378\/chest.11-2303_bib114","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1378\/chest.116.5.1333","article-title":"Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia","volume":"116","author":"Wallis","year":"1999","journal-title":"Chest"},{"issue":"3","key":"10.1378\/chest.11-2303_bib115","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/107602960501100306","article-title":"Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia","volume":"11","author":"Hursting","year":"2005","journal-title":"Clin Appl Thromb Hemost"},{"issue":"3","key":"10.1378\/chest.11-2303_bib116","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11239-005-1849-9","article-title":"Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR)","volume":"19","author":"Bartholomew","year":"2005","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"10.1378\/chest.11-2303_bib117","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1586\/ehm.10.54","article-title":"Fondaparinux: does it cause HIT? Can it treat HIT?","volume":"3","author":"Warkentin","year":"2010","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"10.1378\/chest.11-2303_bib118","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1160\/TH09-01-0008","article-title":"Prescription of fondaparinux in hospitalised patients","volume":"101","author":"Baroletti","year":"2009","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1378\/chest.11-2303_bib119","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijoa.2009.01.012","article-title":"Anticoagulation with argatroban in a parturient with heparin-induced thrombocytopenia","volume":"19","author":"Ekbatani","year":"2010","journal-title":"Int J Obstet Anesth"},{"issue":"8","key":"10.1378\/chest.11-2303_bib120","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMcp052967","article-title":"Clinical practice. Heparin-induced thrombocytopenia","volume":"355","author":"Arepally","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1378\/chest.11-2303_bib121","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/107602960300900103","article-title":"On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia","volume":"9","author":"Schenk","year":"2003","journal-title":"Clin Appl Thromb Hemost"},{"issue":"6","key":"10.1378\/chest.11-2303_bib122","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1160\/TH05-07-0489","article-title":"Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004","volume":"95","author":"Magnani","year":"2006","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1378\/chest.11-2303_bib123","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1034\/j.1600-0609.2003.00105.x","article-title":"Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures","volume":"71","author":"Kodityal","year":"2003","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1378\/chest.11-2303_bib124","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.athoracsur.2006.09.038","article-title":"Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial","volume":"83","author":"Koster","year":"2007","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1378\/chest.11-2303_bib125","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.athoracsur.2007.04.007","article-title":"Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four\/heparin antibodies [see comment]","volume":"84","author":"Dyke","year":"2007","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1378\/chest.11-2303_bib126","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jtcvs.2005.10.049","article-title":"Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study","volume":"131","author":"Smedira","year":"2006","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"10.1378\/chest.11-2303_bib127","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jtcvs.2005.09.057","article-title":"A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study","volume":"131","author":"Dyke","year":"2006","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"10.1378\/chest.11-2303_bib128","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.athoracsur.2003.09.061","article-title":"Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery","volume":"77","author":"Merry","year":"2004","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1378\/chest.11-2303_bib129","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/cr.2000.5861","article-title":"Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients","volume":"14","author":"Koster","year":"2000","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"6","key":"10.1378\/chest.11-2303_bib130","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.athoracsur.2003.09.034","article-title":"Heparin-induced thrombocytopenia and cardiac surgery","volume":"76","author":"Warkentin","year":"2003","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"10.1378\/chest.11-2303_bib131","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1055\/s-2006-955956","article-title":"Recombinant hirudin for cardiopulmonary bypass anticoagulation: a randomized, prospective, and heparin-controlled pilot study","volume":"55","author":"Riess","year":"2007","journal-title":"Thorac Cardiovasc Surg"},{"issue":"2","key":"10.1378\/chest.11-2303_bib132","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1213\/00000539-200302000-00009","article-title":"Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series","volume":"96","author":"Nuttall","year":"2003","journal-title":"Anesth Analg"},{"issue":"2","key":"10.1378\/chest.11-2303_bib133","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1067\/mtc.2003.103","article-title":"Heparin versus danaparoid in off-pump coronary bypass grafting: results of a prospective randomized clinical trial","volume":"125","author":"Carrier","year":"2003","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"10.1378\/chest.11-2303_bib134","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1053\/cr.2000.5846","article-title":"Management of urgent high-risk cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and coexisting disorders of renal function: use of heparin and epoprostenol combined with on-line monitoring of platelet function","volume":"14","author":"Mertzlufft","year":"2000","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"2","key":"10.1378\/chest.11-2303_bib135","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0003-4975(00)02022-1","article-title":"Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia","volume":"71","author":"Aouifi","year":"2001","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"10.1378\/chest.11-2303_bib136","first-page":"354","article-title":"Cardiac surgery in patients with heparin-induced thrombocytopenia using preoperatively determined dosages of iloprost","volume":"5","author":"Antoniou","year":"2002","journal-title":"Heart Surg Forum"},{"issue":"6","key":"10.1378\/chest.11-2303_bib137","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0003-4975(00)01888-9","article-title":"Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb\/IIIa inhibitor tirofiban as anticoagulant","volume":"70","author":"Koster","year":"2000","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1378\/chest.11-2303_bib138","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ijcard.2010.08.007","article-title":"Comparison of bivalirudin versus heparin plus glycoprotein IIb\/IIIa inhibitors in patients undergoing an invasive strategy: A meta-analysis of randomized clinical trials","volume":"152","author":"Lee","year":"2010","journal-title":"Int J Cardiol"},{"issue":"11","key":"10.1378\/chest.11-2303_bib139","first-page":"611","article-title":"The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results","volume":"15","author":"Mahaffey","year":"2003","journal-title":"J Invasive Cardiol"},{"issue":"11","key":"10.1378\/chest.11-2303_bib140","first-page":"617","article-title":"Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia","volume":"15","author":"Cochran","year":"2003","journal-title":"J Invasive Cardiol"},{"issue":"2","key":"10.1378\/chest.11-2303_bib141","first-page":"177","article-title":"Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia","volume":"57","author":"Lewis","year":"2002","journal-title":"Catheter Cardiovasc Interv"},{"issue":"12","key":"10.1378\/chest.11-2303_bib142","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0002-9149(01)02119-1","article-title":"Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention","volume":"88","author":"Roe","year":"2001","journal-title":"Am J Cardiol"},{"issue":"22","key":"10.1378\/chest.11-2303_bib143","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1093\/eurheartj\/ehi590","article-title":"Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention","volume":"26","author":"Sinnaeve","year":"2005","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1378\/chest.11-2303_bib144","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/euhj.2001.2731","article-title":"Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention","volume":"23","author":"Mehta","year":"2002","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1378\/chest.11-2303_bib145","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11239-004-0171-2","article-title":"Argatroban anticoagulation in conjunction with glycoprotein IIb\/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study","volume":"18","author":"Jang","year":"2004","journal-title":"J Thromb Thrombolysis"},{"issue":"13","key":"10.1378\/chest.11-2303_bib146","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"issue":"3","key":"10.1378\/chest.11-2303_bib147","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0002-9343(87)90748-0","article-title":"Hemodialysis without anticoagulation. One-year prospective trial in hospitalized patients at risk for bleeding","volume":"83","author":"Schwab","year":"1987","journal-title":"Am J Med"},{"issue":"2","key":"10.1378\/chest.11-2303_bib148","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1053\/j.ajkd.2009.03.012","article-title":"Antibodies to heparin-platelet factor 4 complex: pathogenesis, epidemiology, and management of heparin-induced thrombocytopenia in hemodialysis","volume":"54","author":"Davenport","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1378\/chest.11-2303_bib149","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/j.1523-1755.2004.66022.x","article-title":"A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease","volume":"66","author":"Murray","year":"2004","journal-title":"Kidney Int"},{"issue":"1","key":"10.1378\/chest.11-2303_bib150","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/CCM.0b013e3181932394","article-title":"Argatroban for anticoagulation in continuous renal replacement therapy","volume":"37","author":"Link","year":"2009","journal-title":"Crit Care Med"},{"issue":"10","key":"10.1378\/chest.11-2303_bib151","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1345\/aph.1G033","article-title":"Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy","volume":"39","author":"Reddy","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1378\/chest.11-2303_bib152","doi-asserted-by":"crossref","first-page":"R102","DOI":"10.1186\/cc6119","article-title":"Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study","volume":"11","author":"de Pont","year":"2007","journal-title":"Crit Care"},{"issue":"4","key":"10.1378\/chest.11-2303_bib153","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1016\/j.thromres.2009.10.008","article-title":"A review of 122 published outcomes of danaparoid anticoagulation for intermittent haemodialysis","volume":"125","author":"Magnani","year":"2010","journal-title":"Thromb Res"},{"issue":"5","key":"10.1378\/chest.11-2303_bib154","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1053\/ajkd.2002.36331","article-title":"Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients","volume":"40","author":"Polkinghorne","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1378\/chest.11-2303_bib155","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1055\/s-0038-1657872","article-title":"The effectiveness of a low molecular weight heparinoid in chronic intermittent haemodialysis","volume":"54","author":"Henny","year":"1985","journal-title":"Thromb Haemost"},{"issue":"14","key":"10.1378\/chest.11-2303_bib156","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1161\/01.CIR.100.14.1528","article-title":"Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin","volume":"100","author":"Song","year":"1999","journal-title":"Circulation"},{"issue":"7","key":"10.1378\/chest.11-2303_bib157","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood.V96.7.2373","article-title":"Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance","volume":"96","author":"Eichler","year":"2000","journal-title":"Blood"},{"issue":"3","key":"10.1378\/chest.11-2303_bib158","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1081\/JDI-120039529","article-title":"Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy","volume":"26","author":"Hein","year":"2004","journal-title":"Ren Fail"},{"issue":"4","key":"10.1378\/chest.11-2303_bib159","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s001340100907","article-title":"Hirudin versus heparin for anticoagulation in continuous renal replacement therapy","volume":"27","author":"Vargas Hein","year":"2001","journal-title":"Intensive Care Med"},{"issue":"72","key":"10.1378\/chest.11-2303_bib160","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1046\/j.1523-1755.56.s72.2.x","article-title":"Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis","author":"Fischer","year":"1999","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"10.1378\/chest.11-2303_bib161","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/ndt\/gfh544","article-title":"Use of fondaparinux (ARIXTRA) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II","volume":"20","author":"Haase","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1378\/chest.11-2303_bib162","first-page":"370","article-title":"Sulodexide for hemodialysis anticoagulation in heparin-induced thrombocytopenia type II","volume":"20","author":"Borawski","year":"2007","journal-title":"J Nephrol"},{"issue":"2","key":"10.1378\/chest.11-2303_bib163","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/CCM.0b013e3181953c5e","article-title":"Citrate anticoagulation for continuous venovenous hemofiltration","volume":"37","author":"Oudemans-van Straaten","year":"2009","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1378\/chest.11-2303_bib164","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s00134-003-2047-x","article-title":"Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study","volume":"30","author":"Monchi","year":"2004","journal-title":"Intensive Care Med"},{"issue":"11","key":"10.1378\/chest.11-2303_bib165","first-page":"1228","article-title":"Citrate versus heparin anticoagulation in chronic haemodialysis patients","volume":"8","author":"Janssen","year":"1993","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1378\/chest.11-2303_bib166","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1053\/j.ajkd.2009.01.259","article-title":"Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single-center randomized controlled trial","volume":"53","author":"Power","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1378\/chest.11-2303_bib167","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.thromres.2009.06.006","article-title":"An analysis of clinical outcomes of 91 pregnancies in 83 women treated with danaparoid (Orgaran)","volume":"125","author":"Magnani","year":"2010","journal-title":"Thromb Res"},{"issue":"2 pt 2","key":"10.1378\/chest.11-2303_bib168","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/AOG.0b013e31817788e0","article-title":"Lepirudin for treatment of acute thrombosis during pregnancy","volume":"112","author":"Chapman","year":"2008","journal-title":"Obstet Gynecol"},{"issue":"8 suppl","key":"10.1378\/chest.11-2303_bib169","first-page":"ECR40","article-title":"Heparin- induced thrombocytopenia occurring in the first trimester of pregnancy: successful treatment with lepirudin. A case report","volume":"91","author":"Furlan","year":"2006","journal-title":"Haematologica"},{"issue":"9","key":"10.1378\/chest.11-2303_bib170","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1111\/j.1538-7836.2004.00883.x","article-title":"Treatment of heparin induced thrombocytopenia and thrombosis during the first trimester of pregnancy","volume":"2","author":"Mehta","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1378\/chest.11-2303_bib171","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00595-007-3570-0","article-title":"Emergency pulmonary embolectomy during the second trimester of pregnancy: report of a case","volume":"38","author":"Taniguchi","year":"2008","journal-title":"Surg Today"},{"issue":"12","key":"10.1378\/chest.11-2303_bib172","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1592\/phco.28.12.1531","article-title":"Successful use of argatroban during the third trimester of pregnancy: case report and review of the literature","volume":"28","author":"Young","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1378\/chest.11-2303_bib173","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1182\/blood-2006-03-009548","article-title":"Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy","volume":"108","author":"Mazzolai","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1378\/chest.11-2303_bib174","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1160\/TH06-10-0577","article-title":"Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids","volume":"97","author":"Gerhardt","year":"2007","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1378\/chest.11-2303_bib175","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.thromres.2006.03.008","article-title":"Treatment of a woman with lupus and thromboembolism and cutaneous intolerance to heparins using fondaparinux during pregnancy","volume":"119","author":"Harenberg","year":"2007","journal-title":"Thromb Res"},{"issue":"4","key":"10.1378\/chest.11-2303_bib176","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0049-3848(00)00253-X","article-title":"A new therapeutic option by subcutaneous recombinant hirudin in patients with heparin-induced thrombocytopenia type II: a pilot study","volume":"99","author":"Huhle","year":"2000","journal-title":"Thromb Res"},{"issue":"8","key":"10.1378\/chest.11-2303_bib177","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/j.1538-7836.2010.03926.x","article-title":"Fondaparinux as an alternative anticoagulant therapy during pregnancy","volume":"8","author":"Knol","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1378\/chest.11-2303_bib178","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1600-0897.2009.00733.x","article-title":"A retrospective analysis of fondaparinux versus enoxaparin treatment in women with infertility or pregnancy loss","volume":"62","author":"Winger","year":"2009","journal-title":"Am J Reprod Immunol"},{"issue":"18","key":"10.1378\/chest.11-2303_bib179","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1056\/NEJM200404293501825","article-title":"Minor transplacental passage of fondaparinux in vivo","volume":"350","author":"Dempfle","year":"2004","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1378\/chest.11-2303_bib180","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1056\/NEJM200008173430718","article-title":"Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia [letter]","volume":"343","author":"P\u00f6tzsch","year":"2000","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1378\/chest.11-2303_bib181","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1538-7836.2009.03734.x","article-title":"Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia","volume":"8","author":"Wanaka","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1378\/chest.11-2303_bib182","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1378\/chest.10-1599","article-title":"Prevalence and risk of pre-existing heparin-induced thrombocytopenia antibodies in patients with acute VTE","volume":"140","author":"Warkentin","year":"2011","journal-title":"Chest"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369212601305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369212601305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:33:22Z","timestamp":1757918002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369212601305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":182,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0012369212601305"],"URL":"https:\/\/doi.org\/10.1378\/chest.11-2303","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718390768.793495356","asserted-by":"object"}]},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment and Prevention of Heparin-Induced Thrombocytopenia","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1378\/chest.11-2303","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}